Tafalgie Therapeutics is conducting research to decode the cellular and molecular mechanisms that underlie analgesic actions. The company aims to develop a new treatment capable of relieving and preventing pain. Its recent activities include securing a €380,000 research grant from the European Regional Development Fund (FEDER). CEO Eric Schettini described the FEDER support as validation of the company’s mission. The article did not report revenue, users, founding year, location, or prior funding rounds.

Total raised

$15M

Funding rounds

2

Latest round

Grant

Latest activity

Jun 2026